Ganirelix
Ganirelix[edit]
Ganirelix is a synthetic decapeptide that acts as a gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in assisted reproduction to prevent premature ovulation during controlled ovarian hyperstimulation.
Mechanism of Action[edit]
Ganirelix works by competitively binding to the gonadotropin-releasing hormone receptors in the pituitary gland. This action inhibits the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which are crucial for the maturation and release of oocytes from the ovaries. By suppressing these hormones, Ganirelix effectively prevents premature ovulation, allowing for better timing of oocyte retrieval in in vitro fertilization (IVF) procedures.
Clinical Use[edit]
Ganirelix is administered via subcutaneous injection. It is typically used in assisted reproductive technology (ART) protocols, particularly in IVF cycles. The drug is usually started in the mid-to-late follicular phase of the menstrual cycle, following the initiation of follicle-stimulating hormone (FSH) therapy.
Dosage and Administration[edit]
The standard dosage of Ganirelix is 250 micrograms per day. It is administered until the day of human chorionic gonadotropin (hCG) administration, which is used to trigger final oocyte maturation.
Side Effects[edit]
Common side effects of Ganirelix include abdominal pain, headache, and injection site reactions such as redness or swelling. Rarely, it may cause hypersensitivity reactions.
Advantages[edit]
Ganirelix offers several advantages in ART protocols, including a reduced risk of ovarian hyperstimulation syndrome (OHSS) compared to gonadotropin-releasing hormone agonist protocols. It also allows for a shorter duration of treatment and more flexible scheduling of oocyte retrieval.
